Mirikizumab-Mrkz Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 100 mg
Reference Brands: Omvoh (USA)
Category: Immune Disorder
Mirikizumab-mrkz is available in Injection and strengths such as 100 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Mirikizumab-mrkz is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Mirikizumab-mrkz can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Mirikizumab‑MRKZ, marketed under the brand name Omvoh, is a monoclonal antibody approved for the treatment of moderately to severely active ulcerative colitis in adults. It works by selectively binding to interleukin-23 (IL-23), a cytokine involved in immune-mediated inflammation, and blocking its activity. This targeted mechanism helps reduce inflammation in the gastrointestinal tract and supports mucosal healing, offering a precision-based approach to managing ulcerative colitis.
Administered via subcutaneous injection, Omvoh is designed for patients who have not responded adequately to conventional therapies. The therapy provides a focused immunomodulatory effect while minimizing broader systemic immunosuppression. Patients receiving Omvoh should be monitored for potential adverse events, which most commonly include upper respiratory tract infections, headache, rash, and injection-site reactions. Its development and production are overseen by Eli Lilly and Company in clinical-grade facilities to ensure high-quality manufacturing and safety standards.
Omvoh represents an important therapeutic option in the management of ulcerative colitis, providing targeted disease control and improving patient quality of life through a novel mechanism of action.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
It is used for the treatment of moderately to severely active ulcerative colitis and Crohn’s disease in adults who have inadequate response to conventional therapies.
It is a humanized monoclonal antibody that selectively binds to interleukin-23 (IL-23), inhibiting inflammatory pathways.
It does not have a trade name in this section (see brand name below).
Eli Lilly and Company.
The generic name is mirikizumab‑MRKZ.
Omvoh (USA).
It is manufactured in clinical-grade facilities under Eli Lilly oversight for research, clinical trials, and commercial distribution.
Related Products
Sarilumab
Strength:
150 mg/1.14 mL, 200 mg/1.14 mL
Form: injection (prefilled syringe)
Reference Brands: Kevzara (USA/EU)
View Details
Quick Response Guaranteed | Verified Suppliers
